open access

Vol 64, No 3 (2014)
Research paper (original)
Published online: 2014-06-13
Get Citation

Cost-effectiveness analysis of advanced stage non-small cell lung cancer treatment with cisplatin–vinorelbine and carboplatin–gemcytabine combination regimens

Małgorzata Kanarkiewicz, Marta Zagańczyk, Bogdan Żurawski, Jerzy Tujakowski, Wiesława Windorbska, Jerzy Krysiński
DOI: 10.5603/NJO.2014.0035
·
Nowotwory. Journal of Oncology 2014;64(3):217-223.

open access

Vol 64, No 3 (2014)
Original article
Published online: 2014-06-13

Abstract

Objectives. The aim of the work is to perform an incremental cost-effectiveness analysis of cisplatin–vinorelbine (PN) and carboplatin–gemcytabine (KG) treatment regimens used in advanced stage non-small cell lung cancer (NSCLC) treatment.

Material and methods. Medical records of 99 patients with advanced stage NSCLC were collected retrospectively at the Oncology Center in Bydgoszcz. The patients were treated with one of the regimens to be analysed between 2006 and 2011. The analysis was performed from the payer’s perspective. Only direct medical costs were analysed. Costs of procedures were obtained from the hospital’s price list of medical services as of June 30th, 2012. Incremental and one-way sensitivity analyses were performed.

Results. The average cost of chemotherapy treatment with the PN treatment regimen is higher than that with the KG treatment regimen (25,342.04 PLN and 19,546.80 PLN per patient, respectively). The average survival time of NSCLC patients treated with PN and KG treatment regimens was 12.91 and 10.11 months, respectively. The cost of drugs constitutes the largest part of the total cost of NSCLC treatment with either treatment regimen. The incremental cost-effectiveness ratio (ICER) is 24,836.76 PLN per additional life-year gained.

Conclusion. The analysis showed that the PN treatment regimen is more cost-effective in the treatment of advanced NSCLC, when compared to the KG treatment regimen.

Abstract

Objectives. The aim of the work is to perform an incremental cost-effectiveness analysis of cisplatin–vinorelbine (PN) and carboplatin–gemcytabine (KG) treatment regimens used in advanced stage non-small cell lung cancer (NSCLC) treatment.

Material and methods. Medical records of 99 patients with advanced stage NSCLC were collected retrospectively at the Oncology Center in Bydgoszcz. The patients were treated with one of the regimens to be analysed between 2006 and 2011. The analysis was performed from the payer’s perspective. Only direct medical costs were analysed. Costs of procedures were obtained from the hospital’s price list of medical services as of June 30th, 2012. Incremental and one-way sensitivity analyses were performed.

Results. The average cost of chemotherapy treatment with the PN treatment regimen is higher than that with the KG treatment regimen (25,342.04 PLN and 19,546.80 PLN per patient, respectively). The average survival time of NSCLC patients treated with PN and KG treatment regimens was 12.91 and 10.11 months, respectively. The cost of drugs constitutes the largest part of the total cost of NSCLC treatment with either treatment regimen. The incremental cost-effectiveness ratio (ICER) is 24,836.76 PLN per additional life-year gained.

Conclusion. The analysis showed that the PN treatment regimen is more cost-effective in the treatment of advanced NSCLC, when compared to the KG treatment regimen.

Get Citation
About this article
Title

Cost-effectiveness analysis of advanced stage non-small cell lung cancer treatment with cisplatin–vinorelbine and carboplatin–gemcytabine combination regimens

Journal

Nowotwory. Journal of Oncology

Issue

Vol 64, No 3 (2014)

Article type

Research paper (original)

Pages

217-223

Published online

2014-06-13

Page views

1313

Article views/downloads

1690

DOI

10.5603/NJO.2014.0035

Bibliographic record

Nowotwory. Journal of Oncology 2014;64(3):217-223.

Authors

Małgorzata Kanarkiewicz
Marta Zagańczyk
Bogdan Żurawski
Jerzy Tujakowski
Wiesława Windorbska
Jerzy Krysiński

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl